Logo

Waters Sells $200M in Senior Notes

Jul 01, 2014 | staff reporter

NEW YORK (GenomeWeb News) – Waters has sold $200 million in senior notes in a private placement, it said in a filing with the US Securities and Exchange Commission today.

The firm sold three series of notes in the placement: $100 million of 3.4 percent Series F Senior Notes, due June 30, 2021; $50 million of 3.92 percent Series G Senior Notes, due June 30, 2024; and $50 million of Series H Floating Rate Senior Notes bearing interest at 3 month LIBOR plus 1.25 percent, due June 30, 2024.

Waters said it intends to use the proceeds to repay other outstanding debt and for general corporate purposes.

Filed under

Proteomics & Protein Research
proteomics
Waters
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.